The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD).
Since 2004, fish oil based lipid emulsions have been used in the treatment of intestinal failure associated liver disease, with a noticeable impact on decreasing the incidence of morbidity and mortality of this often fatal condition. With this new therapy, however, different approaches have emerged as well as concerns about potential risks with using fish oil as a monotherapy. This review will discuss the experience to date with this lipid emulsion along with the rational for its use, controversies and concerns.
Boston Children's Hospital, Boston, MA 02215, USA. melissa.chang@childrens.harvard.edu
Melissa I
MI
Chang
Mark
M
Puder
Kathleen M
KM
Gura
D004041:Dietary Fats / Q000627:therapeutic use*; D005217:Fat Emulsions, Intravenous / Q000737:chemistry / Q000627:therapeutic use*; D005395:Fish Oils / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007410:Intestinal Diseases / Q000150:complications*; D008107:Liver Diseases / Q000209:etiology / Q000628:therapy*; D010288:Parenteral Nutrition / Q000009:adverse effects; D013024:Soybean Oil / Q000009:adverse effects / Q000627:therapeutic use*
D004041:Dietary Fats; D005217:Fat Emulsions, Intravenous; D005395:Fish Oils; D013024:Soybean Oil